

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WONG'S KONG KING INTERNATIONAL (HOLDINGS) LIMITED**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 532)**

**RETIREMENT OF DIRECTORS,  
APPOINTMENT OF DIRECTOR,  
RE-DESIGNATION OF DIRECTOR  
AND  
CHANGE OF COMPOSITION OF AUDIT COMMITTEE, REMUNERATION  
COMMITTEE AND NOMINATION COMMITTEE**

The Board of the Company announces that with effect from 1 July 2017:

- (1) Mr. John Ho and Mr. Gene Howard Weiner will retire as the Independent Non-executive Directors of the Company;
- (2) Mr. Tse Hin Lin Arnold will be appointed as an Independent Non-executive Director of the Company;
- (3) Dr. Leung Kam Fong will be re-designated from a Non-executive Director to an Independent Non-executive Director of the Company;
- (4) Mr. John Ho will resign as the chairman of each of the Audit Committee and the Remuneration Committee, and a member of the Nomination Committee of the Company;
- (5) Mr. Tse Wan-Chung Philip, an Independent Non-executive Director, will be appointed as the chairman of each of the Audit Committee and the Remuneration Committee of the Company; and
- (6) Dr. Leung Kam Fong, an Independent Non-executive Director, will be appointed as a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee of the Company.

**RETIREMENT OF DIRECTORS**

The Board of Directors (the “**Board**”) of Wong’s Kong King International (Holdings) Limited (the “**Company**”) announces that with effect from 1 July 2017:

- Mr. John Ho (“**Mr. Ho**”) will retire from his position as an Independent Non-executive Director of the Company; and
- Mr. Gene Howard Weiner (“**Mr. Weiner**”) will retire from his position as an Independent Non-executive Director of the Company.

Mr. Ho and Mr. Weiner have confirmed that they have no disagreement with the Board and they are not aware of any matters relating to their respective retirement that need to be brought to the attention of the shareholders of the Company. The Board would like to express its sincere gratitude to Mr. Ho and Mr. Weiner for their valuable contributions to the Company during their tenure with the Company.

## **APPOINTMENT OF DIRECTOR**

The Board also announces that Mr. Tse Hin Lin Arnold (“**Mr. Tse**”) will be appointed as an Independent Non-executive Director of the Company with effect from 1 July 2017.

Mr. Tse, aged 64, holds a Bachelor’s Degree in Social Science (Statistics and Geography) and also a Law Degree. Mr. Tse had practiced as a barrister in Hong Kong between 1987 and 1988. He was admitted as a solicitor in 1990 and founded ATL Law Offices on 1 July 2008. Upon his retirement from partnership in April 2013, Mr. Tse has been acting as the consultant solicitor of ATL Law Offices until his retirement in October 2014. Mr. Tse has practiced commercial and corporate law, including advising on cross-border acquisitions and commercial transactions. He has acted as an Independent Non-executive Director of each of Evergrande Health Industry Group Limited (formerly known as New Media Group Holdings Limited) (Stock Code: 708) and Emperor Capital Group Limited (Stock Code: 717) between January 2008 to November 2013 and March 2014 to July 2015 respectively. Both of the aforesaid companies whose issued shares are listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”). During the aforesaid periods, Mr. Tse also served several Committees of the aforesaid companies.

Mr. Tse does not hold any position with the Company and its subsidiaries. Save as disclosed above, He does not hold any directorships in the last three years in public companies the securities of which are listed on any securities market in Hong Kong or overseas. Mr. Tse does not have any relationship with any directors, senior management, substantial or controlling shareholders of the Company. As at the date of this announcement, Mr. Tse does not have any interests in shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (the “**SFO**”).

There is no service contract between the Company and Mr. Tse. He is not appointed for a specific term but shall be subject to the relevant provisions of retirement and re-election at the annual general meetings of the Company in accordance with the bye-laws of the Company.

Pursuant to a letter of appointment signed between Mr. Tse and the Company, Mr. Tse is entitled to receive a director’s fee of HK\$120,000 per annum. The fees payable to the Directors are determined by the Board with reference to the Directors’ duties and responsibilities in the Company and the prevailing market conditions.

Mr. Tse has confirmed that he meets the independence guidelines set out in Rule 3.13 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

Save as disclosed above, there are no other matters concerning the appointment of Mr. Tse that need to be brought to the attention of the shareholders of the Company nor is there any information that is required to be disclosed pursuant to the requirements of Rule 13.51(2) of the Listing Rules.

The Board would like to extend a warm welcome to Mr. Tse on his appointment.

## **RE-DESIGNATION OF A NON-EXECUTIVE DIRECTOR AS AN INDEPENDENT NON-EXECUTIVE DIRECTOR**

The Board further announces that Dr. Leung Kam Fong (“**Dr. Leung**”) will be re-designated from a Non-executive Director to an Independent Non-executive Director of the Company with effect from 1 July 2017.

Dr. Leung, aged 75, obtained a Bachelor of Science degree and a post-graduate Certificate in Education from the University of Hong Kong. Dr. Leung began his career in technical education and training in 1965 at the Hong Kong Technical College and Hong Kong Polytechnic. He joined the Vocational Training Council in 1982, founded the Chai Wan Technical Institute in 1985, upgraded it to Hong Kong Technical College (Chai Wan) in 1992 and subsequently became Deputy Executive Director in 1993. In 1995, he was appointed as the Chief Executive of Tung Wah Group of Hospitals until 2006. In these 11 years, Tung Wah experienced tremendous expansion, and he pioneered the development of a series of modern Chinese Medicine Specialist Clinics. He was awarded honorary doctorate degrees from Middlesex University, U. K. and Hunan University of Traditional Chinese Medicine, PRC and holds visiting professorship at Hunan and Chengdu University of Traditional Chinese Medicine, PRC. He had been appointed Vice-Secretary General of the World Federation of Chinese Medicine Societies, PRC from 2006 to 2010. He was elected President of the International Hua-Xia Medicine Society. Dr. Leung joined the Group in 2007 as the executive director and the chief executive of 3 Kings Holding Limited (“**3 Kings Holding**”), a subsidiary of the Company formed to conduct business in health care and Chinese medicine. Dr. Leung was also appointed as the director of 3 Kings Advertising Company Limited (“**3 Kings Advertising**”), a subsidiary of the Company, since 2009. Dr. Leung resigned from all his positions in 3 Kings Holding and 3 Kings Advertising in January 2013. Dr. Leung was appointed as a director of the Modernized Chinese Medicine International Association in 2013. He has been a Non-executive Director of the Company since January 2013. Save as disclosed above, Dr. Leung did not hold any other directorships in the last three years in any other public companies, the securities of which are listed in Hong Kong or overseas.

There is no service contract entered into between Dr. Leung and the Company. Dr. Leung does not have any relationship with any Director, senior management, substantial or controlling shareholders (as defined in the Listing Rules) of the Company. As at the date of this announcement, Dr. Leung and his wife are interested in 180,000 Shares of the Company, representing approximately 0.02% of the total number of shares of the Company in issue. Save as disclosed above, Dr. Leung does not have any other interest or short position in shares, underlying shares or debentures of the Company or any of its associated corporations within the meaning of Part XV of the SFO.

Pursuant to a letter of appointment signed between Dr. Leung and the Company, Dr. Leung was not appointed for a specific term but is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the provisions of the bye-laws of the Company. Dr. Leung is entitled to receive a director’s fee of HK\$120,000 per annum and an audit committee member’s fee of HK\$60,000 per annum. The fees payable to the Directors are determined by the Board with reference to the Directors’ duties and responsibilities in the Company and the prevailing market conditions.

Dr. Leung was a Non-executive Director of the Company during the two years immediately prior to his re-designation as an Independent Non-executive Director of the Company. Dr. Leung has never had any involvement in the core business of the Company. Since his appointment as a Non-executive Director of the Company in January 2013, Dr. Leung has not held any executive or management role or function in the Company or any of its subsidiaries, nor has he been employed by the Company or any of its subsidiaries since then. He has not taken part in the day-to-day management of the Company or its subsidiaries beyond his attendance at and participation in board meetings of the Company. He has not previously served on any of the Audit, Remuneration or Nomination Committees of the Company. He does not have any business and/or financial relationship or other connection with any director, senior management, substantial or controlling shareholder of the Company. Dr. Leung has confirmed that he has satisfied all the factors set out in Rule 3.13 of the Listing Rules in assessing his independence. Accordingly, the Board is satisfied and the Company has demonstrated to the satisfaction of the Hong Kong Stock Exchange that Dr. Leung is independent for the purpose of his re-designation as an Independent Non-executive Director of the Company pursuant to Rule 3.13 of the Listing Rules.

Save as disclosed above, there are no other matters concerning the re-designation of Dr. Leung as an Independent Non-executive Director that need to be brought to the attention of the shareholders of the Company nor any information to be disclosed pursuant to the requirements of Rule 13.51(2) of the Listing Rules.

The Board wishes to express its sincere gratitude to Dr. Leung for his invaluable contribution to the Company during the tenure of his office as Non-executive Director, and warmly welcomes him in his new role in the Company.

Following the above changes, the Board will comprise (i) five Executive Directors, namely Mr. Senta Wong, Mr. Tsui Ying-Chun Edward, Mr. Ho Shu-Chan Byron, Mr. Kwong Man-Hang Bengie and Mr. Hamed Hassan El-Abd; (ii) one Non-executive Director, namely Mr. Hsu Hung Chieh; and (iii) four Independent Non-executive Directors, namely Mr. Tse Wan-Chung Philip, Dr. Leung Kam Fong, Dr. Yip Wai Chun and Mr. Tse Hin Lin Arnold.

## **CHANGE OF COMPOSITION OF THE AUDIT COMMITTEE, THE REMUNERATION COMMITTEE AND THE NOMINATION COMMITTEE**

The Board finally announces that with effect from 1 July 2017:

- Mr. John Ho will resign as the chairman of each of the audit committee of the Board (the “**Audit Committee**”) and the remuneration committee of the Board (the “**Remuneration Committee**”), and a member of the nomination committee of the Board (the “**Nomination Committee**”);
- Mr. Tse Wan-Chung Philip, an Independent Non-executive Director, will be appointed as the chairman of each of the Audit Committee and the Remuneration Committee; and
- Dr. Leung Kam Fong, an Independent Non-executive Director, will be appointed as a member of each of the Audit Committee, the Remuneration Committee and the Nomination Committee.

Following the above changes;

- (1) The Audit Committee comprises Mr. Tse Wan-Chung Philip, Dr. Leung Kam Fong and Dr. Yip Wai Chun of which Mr. Tse Wan-Chung Philip is the chairman;
- (2) The Remuneration Committee comprises Mr. Tse Wan-Chung Philip, Dr. Leung Kam Fong and Dr. Yip Wai Chun of which Mr. Tse Wan-Chung Philip is the chairman; and
- (3) The Nomination Committee comprises Mr. Senta Wong, Mr. Tse Wan-Chung Philip and Dr. Leung Kam Fong, of which Mr. Senta Wong is the chairman.

By Order of the Board  
**Wong's Kong King International (Holdings) Limited**  
**Senta Wong**  
*Chairman*

Hong Kong, 26 June 2017

As at the date of this announcement, the Executive Directors of the Company are Mr. Senta Wong, Mr. Edward Ying-Chun Tsui, Mr. Byron Shu-Chan Ho, Mr. Bengie Man-Hang Kwong and Mr. Hamed Hassan El-Abd; the Non-executive Directors are Dr. Leung Kam Fong and Mr. Hsu Hung Chieh; and the Independent Non-executive Directors of the Company are Mr. John Ho, Mr. Philip Wan-Chung Tse, Mr. Gene Howard Weiner and Dr. Yip Wai Chun.